scispace - formally typeset
M

Michael A. Matthay

Researcher at University of California, San Francisco

Publications -  1063
Citations -  110857

Michael A. Matthay is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Lung injury & Lung. The author has an hindex of 151, co-authored 998 publications receiving 98687 citations. Previous affiliations of Michael A. Matthay include University of California & Cardiovascular Institute of the South.

Papers
More filters
Journal ArticleDOI

Elevated concentrations of leukotriene D4 in pulmonary edema fluid of patients with the adult respiratory distress syndrome

TL;DR: The possible contribution of metabolites of arachidonic acid to the increased permeability of the alveolar-capillary barrier in the adult respiratory distress syndrome was examined by quantifying the pulmonary edema fluid concentrations of lipoxygenase and cyclooxygenases products.
Journal ArticleDOI

Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome

TL;DR: Altered levels of plasma biomarkers may be useful biologic confirmation of the diagnosis of ARDS in patients with sepsis, and also potentially for selecting patients for clinical trials that are designed to reduce lung epithelial injury.
Journal ArticleDOI

Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.

TL;DR: The hypothesis that type II alveolar epithelial cells are centrally involved in the pathobiology of acute exacerbation of idiopathic pulmonary fibrosis is supported and the hypothesis that acute exacerbations of IPF has a distinct plasma biomarker profile from that of acute lung injury is suggested.
Journal ArticleDOI

Pharmacotherapy of Acute Lung Injury and the Acute Respiratory Distress Syndrome

TL;DR: An overview of pharmacological therapies of acute lung injury and the acute respiratory distress syndrome tested in clinical trials and current recommendations for their use are provided as well as a discussion of potential future pharmacology therapies including β2-adrenergic agonist therapy, keratinocyte growth factor, and activated protein C.